EP1046652A4 - Dosage de ldl denaturees - Google Patents

Dosage de ldl denaturees

Info

Publication number
EP1046652A4
EP1046652A4 EP98961418A EP98961418A EP1046652A4 EP 1046652 A4 EP1046652 A4 EP 1046652A4 EP 98961418 A EP98961418 A EP 98961418A EP 98961418 A EP98961418 A EP 98961418A EP 1046652 A4 EP1046652 A4 EP 1046652A4
Authority
EP
European Patent Office
Prior art keywords
ldls
quantitating
denatured
quantitating denatured
denatured ldls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98961418A
Other languages
German (de)
English (en)
Other versions
EP1046652A1 (fr
Inventor
Tatsuya Sawamura
Makoto Kakutani
Tomoh Masaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MASAKI, TOMOH
SAWAMURA, TATSUYA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1046652A1 publication Critical patent/EP1046652A1/fr
Publication of EP1046652A4 publication Critical patent/EP1046652A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98961418A 1997-12-19 1998-12-18 Dosage de ldl denaturees Withdrawn EP1046652A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP36498197 1997-12-19
JP36498197 1997-12-19
JP34964898 1998-12-09
JP34964898 1998-12-09
JP35817098A JP2002017353A (ja) 1997-12-19 1998-12-16 変性ｌｄｌの定量方法
JP35817098 1998-12-16
PCT/JP1998/005744 WO1999032520A1 (fr) 1997-12-19 1998-12-18 Dosage de ldl denaturees

Publications (2)

Publication Number Publication Date
EP1046652A1 EP1046652A1 (fr) 2000-10-25
EP1046652A4 true EP1046652A4 (fr) 2005-02-16

Family

ID=27341318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98961418A Withdrawn EP1046652A4 (fr) 1997-12-19 1998-12-18 Dosage de ldl denaturees

Country Status (4)

Country Link
EP (1) EP1046652A4 (fr)
JP (1) JP2002017353A (fr)
CA (1) CA2315280A1 (fr)
WO (1) WO1999032520A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784677B2 (en) * 2000-03-02 2006-05-25 Abgenix, Inc. Human monoclonal antibodies against oxidized LDL receptor and pharmaceutical uses thereof
WO2003049695A2 (fr) * 2001-12-07 2003-06-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Composes destines a traiter l'infection au vih et le sida
JP2003279571A (ja) * 2002-03-20 2003-10-02 Kyowa Hakko Kogyo Co Ltd 炎症性疾患検出方法、検出薬、およびその予防治療薬探索方法
JP2004125785A (ja) * 2002-09-02 2004-04-22 National Food Research Institute ビオチン化タンパク質を用いる受容体チップおよびその作製方法
US20040209294A1 (en) 2002-09-02 2004-10-21 National Food Research Institute Method to produce a receptor chip using biotinylated protein
WO2007131652A1 (fr) * 2006-05-17 2007-11-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Procédé pour détecter une substance antiathériosclérotique
JP2009082076A (ja) * 2007-09-28 2009-04-23 National Agriculture & Food Research Organization 変異受容体、ならびにこれを用いる生活習慣病関連因子検出方法
WO2010018870A1 (fr) 2008-08-15 2010-02-18 藤倉化成株式会社 Marqueur polypeptidique pour le diagnostic de l'artériosclérose, procédé de détection de l'artériosclérose à l'aide du marqueur ou similaire, et trousse de diagnostic de l'artériosclérose
JP5581432B2 (ja) * 2013-09-17 2014-08-27 株式会社バイオマーカーサイエンス 脳卒中又は脳梗塞の発症リスクの評価方法及び評価用キット
JPWO2021090922A1 (fr) * 2019-11-08 2021-05-14
JPWO2021090923A1 (fr) * 2019-11-08 2021-05-14
JP6826740B1 (ja) * 2020-02-06 2021-02-10 国立大学法人 岡山大学 酸化ＬＤＬ／β２ＧＰＩ複合体の検出方法、及び、検出キット

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795605A1 (fr) * 1994-11-30 1997-09-17 Nippon Chemiphar Co., Ltd. Recepteur de lipoproteine basse densite denature

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586635A1 (fr) * 1990-06-28 2005-10-19 Hoechst Aktiengesellschaft Protéines fusionnées avec des portions d'immunoglobulines, leur production et utilisation
DE4037837A1 (de) * 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795605A1 (fr) * 1994-11-30 1997-09-17 Nippon Chemiphar Co., Ltd. Recepteur de lipoproteine basse densite denature

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MORGANELLI PETER M ET AL: "Evidence that human Fcgamma receptor IIA (CD32) subtypes are not receptors for oxidized LDL", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 17, no. 11, November 1997 (1997-11-01), pages 3248 - 3254, XP002312026, ISSN: 1079-5642 *
SAMBRANO GILBERTO R ET AL: "Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: Role of membrane phosphatidylserine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, no. 5, 1995, pages 1396 - 1400, XP002312025, ISSN: 0027-8424 *
SAMBRANO GILBERTO R ET AL: "Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 8, 1994, pages 3265 - 3269, XP002312024, ISSN: 0027-8424 *
SAWAMURA TATSUYA ET AL: "An endothelial receptor for oxidized low-density lipoprotein", NATURE (LONDON), vol. 386, no. 6620, 3 June 1997 (1997-06-03), pages 73 - 77, XP002312023, ISSN: 0028-0836 *
See also references of WO9932520A1 *

Also Published As

Publication number Publication date
CA2315280A1 (fr) 1999-07-01
JP2002017353A (ja) 2002-01-22
WO1999032520A1 (fr) 1999-07-01
EP1046652A1 (fr) 2000-10-25

Similar Documents

Publication Publication Date Title
HU9801620D0 (en) Method for air ractification
HUP0000911A3 (en) Refuse-treatment method
GB2345063B (en) Method
GB9706282D0 (en) Method
PL334701A1 (en) Novel method
EP1046652A4 (fr) Dosage de ldl denaturees
GB9700320D0 (en) Method
AU4848099A (en) Merchant analysis support method
EP1048739A4 (fr) Methode d'analyse de composants intracellulaires
GB9707744D0 (en) Method
ZA9810471B (en) New method
GB9717652D0 (en) Method
GB9825390D0 (en) Welding method
GB9718226D0 (en) Cooling method
AU1684199A (en) Method for quantitating denatured ldls
GB9702659D0 (en) Distillation method
AU3043497A (en) Method for marking objects
GB9725462D0 (en) Novel method
GB9709811D0 (en) Method
GB9715269D0 (en) Novel method
GB9715150D0 (en) Novel method
GB9705683D0 (en) Novel method
GB9700940D0 (en) Novel method
GB9700256D0 (en) Method
GB9712984D0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MASAKI, TOMOH

Owner name: SAWAMURA, TATSUYA

A4 Supplementary search report drawn up and despatched

Effective date: 20050107

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 17/02 B

Ipc: 7G 01N 33/92 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 07K 17/00 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 07K 14/705 B

Ipc: 7C 07K 19/00 A

17Q First examination report despatched

Effective date: 20070703

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090623